Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences

• Main Authors: Andrea L. Davis (Author), Alexandra M. Stevens (Author), Julienne Brackett (Author), Lucila Marquez (Author), Catherine E. Foster (Author), Adriana Sarmiento Clemente (Author), Hannah E. Sauer (Author), Grant T. Stimes (Author), Judith R. Campbell (Author)
• Format: Book
• Published: Cambridge University Press, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.

Item Description

10.1017/ash.2024.81
2732-494X